What is Modulim?
Modulim operates at the intersection of photonics and clinical diagnostics, utilizing spatial frequency domain imaging (SFDI) to provide non-invasive, high-resolution assessments of tissue health. By enabling clinicians to visualize perfusion and oxygenation in real-time, the company addresses critical gaps in wound care and vascular surgery. This technological edge positions Modulim as a key player in the medical device market, where precision and data-driven insights are paramount for improving patient outcomes and reducing healthcare costs associated with chronic vascular conditions.
How much funding has Modulim raised?
Modulim has raised a total of $12.7M across 5 funding rounds:
Angel/Seed
$500K
Private Equity
$2M
Series A
$2.9M
Series B
$7M
Debt
$350K
Angel/Seed (2016): $500K with participation from The Cove Fund
Private Equity (2017): $2M, investors not publicly disclosed
Series A (2017): $2.9M supported by Hamamatsu, Mitsubishi UFJ Capital Co, Ltd, and Grey Sky Venture Partners
Series B (2019): $7M, investors not publicly disclosed
Debt (2020): $350K backed by PPP
Key Investors in Modulim
Hamamatsu
Hamamatsu Photonics is a global leader in photonics technology, providing high-performance imaging sensors and optical systems essential for medical and scientific research applications.
Mitsubishi UFJ Capital Co, Ltd
A prominent venture capital arm of the Mitsubishi UFJ Financial Group, specializing in providing strategic growth capital and market access to innovative companies targeting the Japanese market.
The Cove Fund
An investment group focused on supporting early-stage ventures, providing the necessary financial backing to help companies transition from initial development to market-ready solutions.
What's next for Modulim?
Following its recent capital infusion, Modulim is well-positioned to scale its commercial operations and expand its clinical footprint. The company's strategic roadmap likely involves deepening its penetration into hospital systems and surgical centers, where its imaging technology can serve as a standard-of-care tool for vascular assessment. As the firm transitions from development to widespread clinical adoption, the focus will shift toward regulatory milestones and the integration of its imaging data into broader electronic health record ecosystems, further cementing its role as an essential partner in modern medical diagnostics.
See full Modulim company page
